There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
NCT05935085
Recruiting
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2024
Locations: AnaptysBio Investigative Site 10-119, Nashville, Tennessee
Conditions: Atopic Dermatitis Eczema
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Nashville, Tennessee
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT05774184
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Vanderbilt University Medical Center-GI Clinical Research Program, Nashville, Tennessee
Conditions: Eosinophilic Esophagitis
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Nashville, Tennessee
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840
Recruiting
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
Register for Updates
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531
Recruiting
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
Gender:
All
Ages:
Between 5 years and 30 years
Trial Updated:
06/03/2024
Locations: Vanderbilt Clinical Research Center, Nashville, Tennessee
Conditions: Hyperphagia in Prader-Willi Syndrome
Register for Updates
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter Phase 1/3 study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended dose (RD) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a do... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Vanderbilt Ingram Cancer Center, Nashville, Tennessee
Conditions: Myelofibrosis
Register for Updates
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Vanderbilt University Medical Center (VUMC), Nashville, Tennessee
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Register for Updates
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
NCT06447844
Recruiting
The study will be a multi-site, randomized, two-arm, controlled clinical trial using OsteoGen® Plug (Test) vs Freeze-dried Bone Allograft with collagen barrier (Control) for alveolar ridge preservation (ARP) in posterior extraction sites with intact buccal cortical plates.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Perio & Implant Associates of Middle TN, Nashville, Tennessee
Conditions: Nonterminal Premolar Needing Extraction
Register for Updates
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
NCT05568888
Recruiting
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Gender:
All
Ages:
15 years and above
Trial Updated:
06/03/2024
Locations: Vanderbilt Hospital and Clinics, Nashville, Tennessee
Conditions: Traumatic Injury
Register for Updates
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
NCT05953337
Recruiting
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/03/2024
Locations: HCA Healthcare Research Institute (Sarah Cannon), Nashville, Tennessee
Conditions: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Register for Updates
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
NCT03193151
Recruiting
INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Vanderbilt University Medical Center, Vanderbilt Transplant Center, Nashville, Tennessee
Conditions: Liver Dysfunction
Register for Updates